| Literature DB >> 7969211 |
O Rascol1, N Fabre, O Blin, J Poulik, U Sabatini, J M Senard, M Ané, J L Montastruc, A Rascol.
Abstract
One month of adjunct treatment with naltrexone (100 mg/day) was compared with placebo in a double-blind, randomized, cross-over design in two groups of patients with Parkinson's disease. The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia. Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. These negative clinical results do not support a significant role of endogenous opioid systems in the pathophysiology of motor impairment in Parkinson's disease.Entities:
Mesh：
Substances：
Year: 1994 PMID： 7969211 DOI： 10.1002/mds.870090410
Source DB: PubMed Journal: Mov Disord ISSN： 0885-3185 Impact factor: 10.338